Biogen, Denali begin late-stage testing o... - Cure Parkinson's

Cure Parkinson's

26,538 members27,954 posts

Biogen, Denali begin late-stage testing of Parkinson’s drugBiogen, Denali begin late-stage testing of Parkinson’s drug

Farooqji profile image
9 Replies

Good News:

The study aims to enroll about 400 participants who test positive for what research indicates is one of the most common genetic drivers of Parkinson’s: mutations in a gene called LRRK2. The drug Biogen and Denali are co-developing, now named BIIB122, is meant to stifle LRRK2, and is being tested against a placebo to see if it can significantly slow the worsening of symptoms in patients with early-stage Parkinson’s.

Bad News:

Results will be available by then end-2031

biopharmadive.com/news/biog...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
9 Replies

Do any of you have an ides why is it gonna take so long?

jeffreyn profile image
jeffreyn in reply to

Maybe they anticipate that it will take a long time to recruit (and process) 400 early-stage PwPs with a specific genetic variant in their LRRK2 gene.

Also, they have only listed 2 locations for this multicentre Phase 3 trial, but this could change quite rapidly.

in reply tojeffreyn

that makes sense.

jocelyng profile image
jocelyng

Sounds like the study that I was going to participate in. (I was ultimately disqualified.) it’s just starting phase 2.

jeffreyn profile image
jeffreyn in reply tojocelyng

This one is a Phase 3 trial.

clinicaltrials.gov/ct2/show...

jaybar profile image
jaybar

Are they looking for LRRK2 subjects? I have that variant. But I’m also on Sinemet since March.

jeffreyn profile image
jeffreyn in reply tojaybar

clinicaltrials.gov/ct2/show...

jeffreyn profile image
jeffreyn

See also this recent PNT article.

Dosing Begins for Phase 3 LIGHTHOUSE Study of BIIB122:

parkinsonsnewstoday.com/new...

jeffreyn profile image
jeffreyn

This recent AlzForum article may also be of interest.

LRRK2 Variants Keep α-Synuclein from Forming Tetramers:

alzforum.org/news/research-...

Not what you're looking for?

You may also like...

Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered

New clinical trial registered: Biogen and Denaliti have initiated the 2nd late-stage study of...

Clinical trial suggests Parkinson's drug is safe in humans

A new study finds an experimental drug that is significant for PD treatment " A large team of...
Abdiqani profile image

Biogen Receives Accelerated Approval for Alzheimer's drug. Accelerated Approval with Follow Up Testing Sounds Good to Me.

Although this doesn't relate to directly to Parkinson’s Disease, I am intrigued by the apparently...
jimcaster profile image

GOOGLE's Founder gives 127 MILLION $$$ to Michael J. Fox Foundation!

"Google co-founder Sergey Brin has given $126.6 million worth of Alphabet stock to the Sergey Brin...

More effective access to the brain . . . probably what Biogen sees in partnering with Denali Therapeutics

Denali Therapeutics certainly seems to be in the “fast lane” in using their proprietary ETV...
redhawk1 profile image